HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC

BACKGROUND: Immune checkpoint blockade (ICB) only works well for a certain subset of patients with non-small cell lung cancer (NSCLC). Therefore, biomarkers for patient stratification are desired, which can suggest the most beneficial treatment. METHODS: In this study, three datasets (GSE126044, GSE...

Descripción completa

Detalles Bibliográficos
Autores principales: Mei, Jie, Jiang, Guanyu, Chen, Yundi, Xu, Yongrui, Wan, Yuan, Chen, Ruo, Liu, Feng, Mao, Wenjun, Zheng, Mingfeng, Xu, Junying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258174/
https://www.ncbi.nlm.nih.gov/pubmed/35794593
http://dx.doi.org/10.1186/s12885-022-09840-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258174/
https://www.ncbi.nlm.nih.gov/pubmed/35794593
http://dx.doi.org/10.1186/s12885-022-09840-6

Ejemplares similares